Skye Bioscience, Inc.
SKYE
$0.72
$0.068.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -48.18% | -227.19% | -123.02% | -121.20% | -120.51% |
| Total Depreciation and Amortization | 2.68% | 171.06% | 527.85% | 542.75% | 517.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -36.56% | 169.43% | -6.79% | 65.18% | 427.45% |
| Change in Net Operating Assets | 451.61% | -341.07% | 405.12% | 64.13% | -686.08% |
| Cash from Operations | -19.50% | -153.95% | -51.49% | -95.10% | -112.58% |
| Capital Expenditure | 100.00% | 100.00% | 100.00% | -96.88% | -614.29% |
| Sale of Property, Plant, and Equipment | 28.21% | 25.55% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -3,201.22% | 651.17% | -36,376.92% | -1,221.63% | 1,391.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 2,329.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.18% | -- | -- | -- | -2,327.16% |
| Cash from Financing | 103.57% | -- | 100.87% | -- | 124.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.48% | 19.54% | -144.88% | -126.79% | -108.47% |